IRCT20251116068013N1 IRCT 2026-05-13 Birjand University of Medical Sciences Investigating the effect of vitamin D on headache severity in adolescents Investigating the effect of vitamin D on headache severity in adolescents with migraine 2026-06-05 anticipated 112 Complete https://irct.ir/trial/88429 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Participants will be assigned to either the intervention or control group using a Block Randomization method with a block size of 4 and an allocation ratio of 1:1. The randomization sequence will be generated by an independent individual (not involved in clinical care or assessment) using computer-generated random numbers. To ensure Allocation Concealment, sequentially numbered, opaque, sealed envelopes will be used. Upon enrollment, each participant will be assigned a serial number and will receive the corresponding envelope to determine their group assignment, Blinding description: To implement blinding, vitamin D supplements will be provided in identical packaging so that the participants (adolescents) remain unaware of their group assignments. Furthermore, the outcome assessor (pediatric neurologist), who evaluates headache severity using the VAS scale and records the frequency of attacks at the end of the third month, will be blinded to the group allocations. Additionally, the statistical analyst will remain blinded to the group identities until the completion of the data analysis process. 3 Migraine in children and adolescents. Intervention 1: The intervention group receives 1000 IU of Vitamin D supplement orally per day for 3 months. In addition, routine treatment including Propranolol tablets (20 mg every 12 hours) and Amitriptyline tablets (25 mg at night) is prescribed. Intervention 2: The control group receives only the routine treatment including Propranolol tablets (20 mg every 12 hours) and Amitriptyline tablets (25 mg at night) for 3 months and will not receive Vitamin D supplements. No - There is not a plan to make this available Justification or reason for not sharing IPD is Individual participant data will not be shared beyond the final results of the study to maintain patient confidentiality.